Hepatocellular carcinoma: Consensus, controversies and future directions: A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting

Canadian Journal of Gastroenterology and Hepatology

Volumn 29, Issue 4, 2015, Pages 178-184

  Burak, Kelly Warren ^a   Sherman, Morris ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diagnosis; Hepatocellular carcinoma; Liver cancer; Practice guidelines; Surveillance; Therapy

Indexed keywords

BRIVANIB; DIETHYLENETRIAMINE; DOXORUBICIN; EVEROLIMUS; SORAFENIB; SUNITINIB;

ARTICLE; BILE DUCT CARCINOMA; CANADA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; CONTRAST ENHANCEMENT; EXPERIMENTAL THERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LIKERT SCALE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NURSING; OCCUPATION; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); CARCINOMA, HEPATOCELLULAR; CONSENSUS DEVELOPMENT; LIVER NEOPLASMS; PROGNOSIS;

CANADA; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 84928945154     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2015/824263     Document Type: Article

References (46)

1. Sherman M, Burak K, Maroun J, et al. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40.
2. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020-2.
3. European Association For The Study Of The Liver; European Organization For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
4. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.
5. Public Health Agency of Canada Mortality Statistics. 〈www.phacaspc.gc.ca/sti-its-surv-epi/model/pdf/model07-eng.pdf〉 (Accessed February 1, 2014).
6. Canadian Cancer Statistics 2013. Special Report: Liver Cancer. 〈www.cancer.ca/en/cancer-information/cancer-101/canadiancancer-tatistics-publication/past-editions-canadian-cancerstatistics/〉 (Accessed February 1, 2014).
7. Leber M, Sherma M. Estimation of immigration-related chronic hepatitis B infection and hepatocellular carcinoma development in Canada from 1981-2006. Can J Gastroenterol 2009;23(Suppl A):A22 (Abst).
8. Myers RP, Krajden M, Bilodeau M, et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol 2014;28:243-50.
9. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004l;130:417-22.
10. Lederle FA, Pocha C. Screening for liver cancer: The rush to judgment. Ann Intern Med 2012;156:387-9.
11. Sharma S, Acarsu U, Hirschfield GM, Feld JJ. Development of a scoring system to predict risk of hepatocellular carcinoma in a cohort of patients with cirrhosis. J Hepatol 2013;58(Suppl 1):S49 (Abst).
12. Yang HI, Yuen MF, Chan HL, et al; REACH-B Working Group. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score. Lancet Oncol 2011;12:568-74.
13. Singal A, Volk ML, Waljee A, et al. Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
14. Singal AG, Marrero JA, Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014;12:375-82.
15. Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012;21:793-9.
16. Yoon SH, Lee JM, So YH, Hong SH, Kim SJ, Han JK, Choi BI. Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: Tumor size and cellular differentiation. AJR Am J Roentgenol 2009;193:482-9.
17. Di Tommaso L, Destro A, Fabbris V, et al. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 2011;53:1549-57.
18. Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): Summary, discussion, consensus of the LI-RADS Management Working Group and future directions. Hepatology 2014; doi: 10.1002/hep.27304 [Epub ahead of print].
19. Vilana R, Forner A, Bianchi L, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010;51:2020-9.
20. Zheng SG, Xu HX, Liu LN. Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. World J Radiol 2014;6:7-14.
21. Jhaveri K, Cleary S, Audet P, et al. A multidisciplinary approach to liver imaging - Consensus statements from a Multidisciplinary Expert Panel on the Utilization and Application of a Liver Specific MR Imaging Contrast Agent (Gd-EOB-DTPA). Am J Roentgenol 2015;204:498-509.
22. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
23. Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012;32:348-59.
24. Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. Liver Transpl 2011;(17 Suppl 2):S44-S57.
25. Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011;140:1501-12.
26. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999;30:1434-40.
27. Cucchetti A, Cescon M, Ercolani G, Bigonzi E, Torzilli G, Pinna AD. A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Ann Surg Oncol 2012;19:3697-705.
28. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453-9.
29. Wang Y, Luo Q, Li Y, Deng S, Wei S, Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: A meta-analysis of randomized and nonrandomized controlled trials. PLoS One 2014;9:e84484.
30. Toso C, Meeberg G, Henandez-Alejandro R, et al. Total tumor volume and alpha fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology 2015, March 17. (Epub ahead of print).
31. Marelli L, Stigliano R, Triantos C, et al.Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25.
32. Lammer J, Malagari K, Vogl T, et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52.
33. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012;56:1330-5.
34. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
35. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009;10:25-34.
36. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-97.
37. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507.
38. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: Chemoembolization versus radioembolization. Am J Transplant 2009;9:1920-8.
39. Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: Review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 2013;87:22-32.
40. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol 2013;31:4067-75.
41. Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as firstline therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517-24.
42. Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2014: pii: JCO.2013.53.7746 (Epub ahead of print).
43. Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-16.
44. Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA 2014;312:57-67.
45. Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY, Cheng AL. Clinical trials in hepatocellular carcinoma: An update. Liver Cancer 2013;2:345-64.
46. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.